« Previous article
WHO and Switzerland ...

31st May 2021  Product update: rapidvirology staff writer

FDA Authorize Radio Frequency-Based Rapid SARS-CoV-2 Antigen Test

Qorvo® (Nasdaq:QRVO), a leading provider of innovative radio frequency (RF) solutions, has entered the SARS-CoV-2 diagnostic market with the Omnia™ SARS-CoV-2 Antigen Test, that has FDA-EUA. The test is authorized for the qualitative detection of nucleocapsid viral antigens from SARS-CoV-2 in nasal swab specimens from individuals who are suspected of COVID-19.

The Qorvo Omnia platform represents a paradigm shift in diagnostic testing capability by using high-frequency Bulk Acoustic Wave (BAW) sensors to achieve SARS-CoV-2 (COVID-19) antigen testing in approximately 20 minutes. BAW sensor technology enables low Limit of Detection (LOD) levels that are similar to molecular testing capability.

The Qorvo Omnia platform features a portable test instrument, a microfluidic cartridge, and secure connectivity. The microfluidic cartridge design enables specific binding with additional wash steps similar to central lab instrument operation and demonstrated results including 100% specificity during clinical trials.

Click here to download the whitepaper on bulk acoustic wave sensors or watch the video below. 



Date Published: 31st May 2021

Source article link: View

Note: This content has been edited by a rapidvirology.com staff writer for style and content.

View full company details

Related news